Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor
Amit Shraga(Weizmann Institute of Science), Nir London(Weizmann Institute of Science), Bruce A. Lefker(Pfizer (United States)), Evgenia Olshvang(Weizmann Institute of Science), Amir Mitchell(University of Massachusetts Chan Medical School), Khriesto A. Shurrush(Weizmann Institute of Science), Sílvia Carvalho(Weizmann Institute of Science), Takayoshi Kinoshita(Osaka Prefecture University), Chakrapani Subramanyam(Pfizer (United States)), Liat Avram(Weizmann Institute of Science), Robert L. Hudkins(State Street (United States)), Nicolas Germain(Weizmann Institute of Science), Tamar Unger(Weizmann Institute of Science), Ziv Shulman(Weizmann Institute of Science), Payam Khoshkenar(University of Massachusetts Chan Medical School), Natalia Davidzohn(Weizmann Institute of Science), Shira Albeck(Weizmann Institute of Science)
Cited by 67
Related Papers
Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery
|ACS Chemical Neuroscience|2011|436
Critical role for Ser20 of human p53 in the negative regulation of p53 by Mdm2
|The EMBO Journal|1999|364
Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening
|Journal of the American Chemical Society|2019|338
The Cancer Microbiome: Distinguishing Direct and Indirect Effects Requires a Systemic View
|Trends in cancer|2020|266
Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine
|Journal of Clinical Investigation|2021|252